Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya

The Monitoring PrEP among Young Adult women (MPYA) Study involved young women at high risk for HIV acquisition, considering age, relationship status, support from a sexual partner, alcohol use, sexual partner HIV status, etc. Participants were offered daily PrEP and followed for two years. Pharmacy refills declined 50% from initiation (Month 0-1) to participation end (Months 22-24) though electronically monitored adherence had moderately high concordance with TDF levels. High adherence was associated with low baseline score, >1 current sexual partner, <=1 hour travel time to clinic, and a specific study site. This study did not include pregnant women at initiation but participants were allowed to continue PrEP if they became pregnant during the study.

Resource Details

Study Type
Observational study
Year
2022
Population
HIV-uninfected women
Author
Haberer JE, Mugo N, Bukusi EA, Ngure K, Kiptinness C, Oware K, Garrison LE, Musinguzi N, Pyra M, Valenzuela S, Thomas KK, Anderson PL, Thirumurthy H, Baeten JM.

More Publications & Resources

Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis

Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-Acting Injectable Pre-Exposure Prophylaxis

PrEP and PEP Guidelines-Zambia

PrEP and PEP Guidelines-Zambia

PrEP Lenacapavir Implementation Guidelines

PrEP Lenacapavir Implementation Guidelines

Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)

Provider Training Toolkit on Use of Oral and Long-acting HIV PrEP: Lenacapavir-Focused Learning Pathway (Lessons 1-4)

Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP

Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP

Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics

Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and Pharmacokinetics

Lenacapavir Provider Tools and Job Aids

Lenacapavir Provider Tools and Job Aids

PrEP Drug Interactions

PrEP Drug Interactions

Zambia PrEP Training Materials for Clinicians and Community Mobilisers

Zambia PrEP Training Materials for Clinicians and Community Mobilisers

HIV Prevention Ambassador Training Package and Toolkit

HIV Prevention Ambassador Training Package and Toolkit

Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection

Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection

National Guidelines for the Management of HIV and AIDS

National Guidelines for the Management of HIV and AIDS

No results found.